JP2009532394A - ポリペプチドの濃縮方法 - Google Patents

ポリペプチドの濃縮方法 Download PDF

Info

Publication number
JP2009532394A
JP2009532394A JP2009503414A JP2009503414A JP2009532394A JP 2009532394 A JP2009532394 A JP 2009532394A JP 2009503414 A JP2009503414 A JP 2009503414A JP 2009503414 A JP2009503414 A JP 2009503414A JP 2009532394 A JP2009532394 A JP 2009532394A
Authority
JP
Japan
Prior art keywords
polypeptide
interest
composition
range
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503414A
Other languages
English (en)
Japanese (ja)
Inventor
ニルソン，ステファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Pharmaceuticals Ireland Ltd
Original Assignee
Shire Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Ireland Ltd filed Critical Shire Pharmaceuticals Ireland Ltd
Publication of JP2009532394A publication Critical patent/JP2009532394A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Water Supply & Treatment (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2009503414A 2006-04-04 2007-04-04 ポリペプチドの濃縮方法 Pending JP2009532394A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
PCT/DK2007/000177 WO2007112757A2 (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009162789A Division JP5384232B2 (ja) 2006-04-04 2009-07-09 ポリペプチドの濃縮方法
JP2013123735A Division JP2013236633A (ja) 2006-04-04 2013-06-12 ポリペプチドの濃縮方法

Publications (1)

Publication Number Publication Date
JP2009532394A true JP2009532394A (ja) 2009-09-10

Family

ID=38472949

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2009503414A Pending JP2009532394A (ja) 2006-04-04 2007-04-04 ポリペプチドの濃縮方法
JP2009162789A Active JP5384232B2 (ja) 2006-04-04 2009-07-09 ポリペプチドの濃縮方法
JP2013123735A Pending JP2013236633A (ja) 2006-04-04 2013-06-12 ポリペプチドの濃縮方法
JP2013207365A Withdrawn JP2014058521A (ja) 2006-04-04 2013-10-02 ポリペプチドの濃縮方法
JP2013207384A Active JP5878152B2 (ja) 2006-04-04 2013-10-02 ポリペプチドの濃縮方法
JP2015223865A Pending JP2016104000A (ja) 2006-04-04 2015-11-16 ポリペプチドの濃縮方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2009162789A Active JP5384232B2 (ja) 2006-04-04 2009-07-09 ポリペプチドの濃縮方法
JP2013123735A Pending JP2013236633A (ja) 2006-04-04 2013-06-12 ポリペプチドの濃縮方法
JP2013207365A Withdrawn JP2014058521A (ja) 2006-04-04 2013-10-02 ポリペプチドの濃縮方法
JP2013207384A Active JP5878152B2 (ja) 2006-04-04 2013-10-02 ポリペプチドの濃縮方法
JP2015223865A Pending JP2016104000A (ja) 2006-04-04 2015-11-16 ポリペプチドの濃縮方法

Country Status (20)

Country Link
US (6) US20090246187A1 (https=)
EP (4) EP2004672B1 (https=)
JP (6) JP2009532394A (https=)
KR (3) KR20140057678A (https=)
CN (1) CN105233276A (https=)
AU (2) AU2007234195B2 (https=)
BR (1) BRPI0709737A2 (https=)
CA (3) CA2644642C (https=)
DK (1) DK2628746T3 (https=)
ES (3) ES2928096T3 (https=)
HU (1) HUE042402T2 (https=)
IL (4) IL194267A (https=)
MX (1) MX2008012748A (https=)
NO (3) NO347673B1 (https=)
NZ (7) NZ623123A (https=)
PL (3) PL2631242T3 (https=)
PT (1) PT2628746T (https=)
SI (1) SI2628746T1 (https=)
WO (1) WO2007112757A2 (https=)
ZA (2) ZA200805346B (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520184A (ja) * 2010-02-24 2013-06-06 ザイムネックス エー／エス 組み換えリソソームα−マンノシダーゼの生産および精製のための方法
JP2016104000A (ja) * 2006-04-04 2016-06-09 シャイア ファーマシューティカルズ アイルランド リミテッドＳｈｉｒｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｒｅｌａｎｄ Ｌｉｍｉｔｅｄ ポリペプチドの濃縮方法
US11642398B2 (en) 2013-03-15 2023-05-09 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
US12128092B2 (en) 2014-03-24 2024-10-29 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
US12168041B2 (en) 2010-06-25 2024-12-17 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536315B2 (en) 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
SMT201600385T1 (it) 2010-06-25 2017-03-08 Shire Human Genetic Therapies Trasporto di agenti terapeutici all’snc
NZ605873A (en) * 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of arylsulfatase a
NZ605874A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of heparan n-sulfatase
ES2625511T3 (es) 2011-07-08 2017-07-19 Shire Human Genetic Therapies, Inc. Métodos para la purificación de arylsulfatasa A
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
CN104854122B (zh) * 2012-11-13 2021-10-08 意大利凯西制药公司 重组人半乳糖脑苷脂-β-半乳糖苷酶(rhGALC)的纯化
AU2013357812B2 (en) * 2012-12-11 2019-10-10 Centogene Gmbh Method for the diagnosis of metachromatic leukodystrophy
AU2014205441B2 (en) 2013-01-09 2019-12-12 Takeda Pharmaceutical Company Limited Methods for purification of arylsulfatase A
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
KR102290596B1 (ko) 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067789A1 (en) * 1999-05-10 2000-11-16 Csl Limited High concentration immunoglobulin preparation and method for its production
JP2002517516A (ja) * 1998-06-09 2002-06-18 スタテンズ セーラム インスティテュート 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
WO2005073367A1 (en) * 2004-01-30 2005-08-11 Zymenex A/S Production and purification of recombinant arylsulfatase a

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
AU750143B2 (en) 1998-01-27 2002-07-11 Zymenex A/S Method for treating acute intermittent porphyria (AIP) and other porphyric diseases
NZ509135A (en) * 1998-06-09 2002-10-25 Statens Seruminstitut A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
WO2001007065A2 (en) * 1999-07-27 2001-02-01 Hemebiotech A/S PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
AU2002317701A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
SI1740204T1 (en) 2004-04-01 2018-07-31 Chiesi Farmaceutici S.P.A. MEDICAL APPLICATION OF ALFA-MANOSIDES
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
ES2928096T3 (es) * 2006-04-04 2022-11-15 Takeda Pharmaceuticals Co Un proceso para la concentración de un polipéptido

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002517516A (ja) * 1998-06-09 2002-06-18 スタテンズ セーラム インスティテュート 静脈投与用免疫グロブリン及び他の免疫グロブリン生成物の製造法
WO2000067789A1 (en) * 1999-05-10 2000-11-16 Csl Limited High concentration immunoglobulin preparation and method for its production
WO2002098455A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
WO2005073367A1 (en) * 2004-01-30 2005-08-11 Zymenex A/S Production and purification of recombinant arylsulfatase a

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMBO J. 5(4):823-826 (1986), JPN7013000504, ISSN: 0002455426 *
J. BIOL. CHEM., vol. 250, no. 7, JPN6012033474, 1975, pages 2495 - 2501, ISSN: 0002262813 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016104000A (ja) * 2006-04-04 2016-06-09 シャイア ファーマシューティカルズ アイルランド リミテッドＳｈｉｒｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｒｅｌａｎｄ Ｌｉｍｉｔｅｄ ポリペプチドの濃縮方法
JP2013520184A (ja) * 2010-02-24 2013-06-06 ザイムネックス エー／エス 組み換えリソソームα−マンノシダーゼの生産および精製のための方法
US10159718B2 (en) 2010-02-24 2018-12-25 Chiesi Farmaceutici S.P.A Process for production and purification of recombinant lysosomal alpha-mannosidase
US12168041B2 (en) 2010-06-25 2024-12-17 Takeda Pharmaceutical Company Limited Methods and compositions for CNS delivery of arylsulfatase A
US12409210B2 (en) 2010-06-25 2025-09-09 Takeda Pharmaceutical Company Limited CNS delivery of therapeutic agents
US11642398B2 (en) 2013-03-15 2023-05-09 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
US12128092B2 (en) 2014-03-24 2024-10-29 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations

Also Published As

Publication number Publication date
CA2632528A1 (en) 2007-10-11
EP2628746A3 (en) 2014-03-19
HUE042402T2 (hu) 2019-06-28
NZ571610A (en) 2011-07-29
WO2007112757A3 (en) 2008-02-28
PT2628746T (pt) 2019-04-23
NZ588903A (en) 2012-08-31
IL211905A0 (en) 2011-05-31
ES2744499T3 (es) 2020-02-25
EP2631242A3 (en) 2013-10-02
NO20084776L (no) 2008-10-31
PL2100898T3 (pl) 2019-11-29
KR101504969B1 (ko) 2015-03-24
AU2007234195A1 (en) 2007-10-11
IL194267A0 (en) 2011-08-01
CA2882501C (en) 2021-09-07
DK2628746T3 (en) 2019-04-01
CN105233276A (zh) 2016-01-13
JP2013236633A (ja) 2013-11-28
EP2628746B1 (en) 2019-01-09
NZ623123A (en) 2015-04-24
JP2014051503A (ja) 2014-03-20
NZ582045A (en) 2011-07-29
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
US20090246187A1 (en) 2009-10-01
US20140314735A1 (en) 2014-10-23
EP2631242B1 (en) 2022-08-03
PL2631242T3 (pl) 2023-03-20
NO20082510L (no) 2008-10-31
EP2100898B1 (en) 2019-06-19
AU2007234195B2 (en) 2013-02-07
CA2644642A1 (en) 2007-10-11
BRPI0709737A2 (pt) 2011-07-26
EP2628746A2 (en) 2013-08-21
NZ568728A (en) 2011-09-30
NZ607595A (en) 2014-10-31
US20160193304A1 (en) 2016-07-07
NO20211305A1 (no) 2008-10-31
AU2008229659B2 (en) 2013-01-31
NZ597548A (en) 2013-08-30
PL2628746T3 (pl) 2019-07-31
CA2644642C (en) 2016-01-26
JP2014058521A (ja) 2014-04-03
IL241654B (en) 2019-02-28
IL194267A (en) 2015-10-29
NO346368B1 (no) 2022-06-27
KR20150103339A (ko) 2015-09-09
NO347673B1 (no) 2024-02-19
JP5878152B2 (ja) 2016-03-08
ES2928096T3 (es) 2022-11-15
JP2016104000A (ja) 2016-06-09
SI2628746T1 (sl) 2019-04-30
JP5384232B2 (ja) 2014-01-08
US20170202927A1 (en) 2017-07-20
IL241654A0 (en) 2015-11-30
EP2004672A2 (en) 2008-12-24
EP2004672B1 (en) 2015-08-19
US20180289777A1 (en) 2018-10-11
KR20140057678A (ko) 2014-05-13
KR20090018894A (ko) 2009-02-24
US9713634B2 (en) 2017-07-25
AU2008229659A1 (en) 2008-10-23
EP2100898A1 (en) 2009-09-16
EP2631242A2 (en) 2013-08-28
CA2882501A1 (en) 2007-10-11
IL235982A0 (en) 2015-01-29
WO2007112757A2 (en) 2007-10-11
ZA200805346B (en) 2018-11-28
US20120076767A1 (en) 2012-03-29
JP2009273469A (ja) 2009-11-26
ZA200809540B (en) 2019-09-25
CA2632528C (en) 2022-07-12
ES2713488T3 (es) 2019-05-22

Similar Documents

Publication Publication Date Title
JP5878152B2 (ja) ポリペプチドの濃縮方法
EP2766477B1 (en) Recombinant human naglu protein and uses thereof
HK1188604A (en) A process for the concentration of a polypeptide
HK1188604B (en) A process for the concentration of a polypeptide
HK1189007B (en) A process for concentration of a polypeptide
HK1189007A (en) A process for concentration of a polypeptide
HK1219671A (en) A process for concentration of a polypeptide
HK1219671A1 (en) A process for concentration of a polypeptide
NZ623690B2 (en) Recombinant human naglu protein and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121029

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130612